Portal de Periódicos da CAPES

B Cells, Viruses, and the SARS-CoV-2/COVID-19 Pandemic of 2020

2020; Mary Ann Liebert, Inc.; Volume: 33; Issue: 4 Linguagem: Inglês

10.1089/vim.2020.0055

1557-8976

Julia L. Hurwitz,

Immune responses and vaccinations

Viral ImmunologyVol. 33, No. 4 IntroductionFree AccessB Cells, Viruses, and the SARS-CoV-2/COVID-19 Pandemic of 2020Julia L. HurwitzJulia L. HurwitzAddress correspondence to: Dr. Julia L. Hurwitz, Department of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA E-mail Address: [email protected]Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.Search for more papers by this authorPublished Online:13 May 2020https://doi.org/10.1089/vim.2020.0055AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookXLinked InRedditEmail This introduction to our “B Cells and Viruses in the Year 2020” issue in Viral Immunology was meant to be celebratory, but the celebration is quelled by a severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) that is circling the globe (3,8). The virus, first identified in December 2019, is causing disease (COVID-19) that affects humans of all ages, particularly the elderly.Currently (March 27, 2020), reports of virus infections are dramatically escalating. In total, there are >597,000 infections and 27,000 deaths among 177 countries or regions. Countries with the most reported infections are the United States (>104,000), Italy (>86,000), China (>81,000), and Spain (>65,0000) (4). In the United States alone, there are >1,700 deaths and 400 of these deaths were reported within the past 24-h period (9). Human B cells (and T cells) have not been sufficiently primed against the emergent SARS-CoV-2 to effectively prevent infection and disease. Experts in B cell (and T cell) research are called to action to provide knowledge and solutions. Immediate needs from B cell immunologists include diagnostic antibody reagents, virus-specific neutralizing polyclonal and monoclonal antibodies, and an effective vaccine (1).How might immunologists harness lymphocytes as weapons against SARS-CoV-2 and other lethal viruses? Evolution has armed human lymphocytes with a sophisticated array of antibody and T cell receptors. During the development of each lymphocyte, gene rearrangements occur (involving V, D, and J gene fragments), resulting in the production of a unique cell surface receptor on each new cell (7). It has been predicted that V-D-J combinatorial diversity may supply humans with more than 1060 different receptors (2), each with a different antigen target. The result is that humans have immune potential toward virtually any new pathogen in nature, including SARS-CoV-2. Since the 1700s, history has shown that virus look-a-like vaccines can be produced to prime virus-specific lymphocytes and activate protective immunity.Once a human is exposed to antigens of a new respiratory virus like SARS-CoV-2, either by natural infection or with a look-a-like vaccine, antigen–antibody interactions at the appropriate B cell surfaces drive virus-specific cell proliferation, antibody isotype switching (through class switch recombination), cell maturation, and cell residence in systemic and mucosal sites. For respiratory viruses, cells and antibodies that reside in upper respiratory tract tissues are particularly effective in that they provide a first line of defense against virus at its point of entry (5,6). After priming against an acute respiratory virus, a healthy immune system is usually protective against future virus exposures and may provide convalescent antibodies for passive protection in naïve hosts (1). Immunity may be nonsterilizing (i.e., there may be limited virus replication after a second virus exposure), but lives are saved by rapid virus clearance and reduction of disease consequences. Even though humans may gain protective immunity from a natural SARS-CoV-2 exposure, the current consequences of COVID-19 at the population level are devastating. The scientific community is urged to develop passive antibody transfer programs and effective vaccines to provide immune protection before, not after, virus exposures.The articles in this issue of Viral Immunology were written before the SARS-CoV-2 pandemic, but are timely in that they provide information necessary for the efficient recruitment and activation of B cells. Articles are categorized into two sections. Section 1 addresses how B cells work with articles from Lefkovits (A few key historical events in the antibody field: The alacritous antibody), New, King, and Kearney (Glycan reactive natural antibodies and viral immunity), Heltzel and Gearhart (What targets somatic hypermutation to the immunoglobulin loci?), Allie and Randall (Resident memory B cells), and Lam, Smith, and Baumgarth (B cell activation and response regulation during viral infections). Section 2 describes influences on B cell development, function, and survival with articles by Jones, Sealy, Penkert, Surman, Birshtein, Xu, Neale, Maul, Gearhart, and Hurwitz (From influenza virus infections to lupus: synchronous estrogen receptor α and RNA polymerase II binding within the immunoglobulin heavy chain locus), Johnson and Tarakanova (Gammaherpesviruses and B cells: Relationship that lasts a lifetime), Sala and Kuka (The suppressive attitude of inflammatory monocytes in antiviral antibody responses), Gyurova, Ali, and Waggoner (Natural killer cell regulation of B cell responses in the context of viral infection [see the cover of this issue to view the virus-induced congregation of natural killer cells [green], B cells [blue] and T cells [red] in the spleen]), and Penkert, Hankins, Young, and Hurwitz (Vaccine design informed by virus-induced immunity). Information in this issue of “B cells and viruses in the year 2020” may expedite the development of new diagnostics, prophylaxes, and therapies to prevent and treat COVID-19. If appropriately harnessed, the human immune system will serve as a formidable enemy against SARS-CoV-2 and any other viruses that threaten human lives.Author Disclosure StatementNo competing financial interests exist.Funding InformationWriting was supported by NIH NCI P30CA21765 and ALSAC.References1. Casadevall A, and Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020;130:1545–1548. Crossref, Medline, Google Scholar2. Dash P, Fiore-Gartland AJ, Hertz T, et al. Quantifiable predictive features define epitope-specific T cell receptor repertoires. Nature 2017;547:89–93. Crossref, Medline, Google Scholar3. Jiang F, Deng L, Zhang L, et al.. Review of the clinical characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med 2020 [Epub ahead of print]; DOI: 10.1007/s11606-020-05762-w. Crossref, Medline, Google Scholar4. Johns Hopkins Corona Virus Resource Center. https://coronavirus.jhu.edu (accessed March 27, 2020). Google Scholar5. Rudraraju R, Surman S, Jones B, et al. Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut. Virology 2011;410:429–436. Crossref, Medline, Google Scholar6. Sealy R, Webby RJ, Crumpton JC, et al. Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccines. Int Immunol 2013;25:183–195. Crossref, Medline, Google Scholar7. Stavnezer J, and Schrader CE. IgH chain class switch recombination: mechanism and regulation. J Immunol 2014;193:5370–5378. Crossref, Medline, Google Scholar8. Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet 2020;395:470–473. Crossref, Medline, Google Scholar9. Worldometer-real time world statistics, COVID-19 Coronavirus pandemic, www.worldometers.info (accessed March 27, 2020). Google ScholarFiguresReferencesRelatedDetailsCited byComputation of Numerical Solution via Non-Standard Finite Difference Scheme8 February 2023The role of antigen-presenting cells in the pathogenesis of COVID-19Pathology - Research and Practice, Vol. 233Study of a COVID-19 mathematical modelHarnessing the Potential of Multiomics Studies for Precision Medicine in Infectious Disease25 September 2021 | Open Forum Infectious Diseases, Vol. 8, No. 11Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testingHeliyon, Vol. 7, No. 4Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID ‐19 prevention and cure12 October 2020 | Phytotherapy Research, Vol. 35, No. 3T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression26 February 2021 | Frontiers in Cellular and Infection Microbiology, Vol. 11A comparative study of the laboratory features of COVID‐19 and other viral pneumonias in the recovery stage21 July 2020 | Journal of Clinical Laboratory Analysis, Vol. 34, No. 10 Volume 33Issue 4May 2020 InformationCopyright 2020, Mary Ann Liebert, Inc., publishersTo cite this article:Julia L. Hurwitz.B Cells, Viruses, and the SARS-CoV-2/COVID-19 Pandemic of 2020.Viral Immunology.May 2020.251-252.http://doi.org/10.1089/vim.2020.0055Published in Volume: 33 Issue 4: May 13, 2020Online Ahead of Print:April 29, 2020PDF download